TNGX Tango Therapeutics Inc

$TNGX Company has 50M in revenue and worth $4B? How? Meanwhile stocks like $SRPT have 1B+ revenue somewhat comparable cash and a robust pipeline and worth less then 2B. Just unbelievable

📅 CATALYST REMINDER | $TNGX October 19, 23 & 25, 2026 — Phase 1/2 Oncology Data Tango Therapeutics will present vopimetostat data in pancreatic ductal adenocarcinoma during ESMO. More details in our hub. #TNGX #Biotech #ESMO2026

$TNGX Chart is more bullish than bearish here but it can still sink lower. Volume today tells me people are buying...

$TNGX -Stifel reiterated its Buy rating on Tango Therapeutics ($TNGX) and maintained its $40 price target. Key Takeaways from Stifel's Update: * Efficacy Validation: Stifel views the Phase 1/2 pancreatic cancer combination data (particularly the high response rates and durability signals alongside Revolution Medicines' RAS inhibitors) as clear clinical validation of the MTAP-synthetic lethality mechanism. * Phase 3 Path: They view the direct progression to a randomized Phase 3 trial in first-line (1L) pancreatic cancer as commercially transformative, justifying long-term upside well above current trading levels. * Viewing the Pullback as an Opportunity: Stifel treated today's dip as event-driven volatility and profit-taking rather than an impairment of the core investment thesis, keeping their $40 target intact (representing roughly 60%–70% upside from current levels).

$TNGX -The pullback in $TNGX reflects a textbook biotech "sell the news" reaction rather than a clinical breakdown. After running aggressively into the ESMO data release, shares are de-risking as short-term momentum traders exit and the market digests a Phase 3 initiation timeline set for early 2027. Clinically, however, the updated Phase 1/2 readout for vopimetostat (TNG462) in combination with RAS(ON) inhibitors demonstrated unprecedented biological activity in pancreatic cancer, transforming a high-risk early-stage asset into a de-risked, registrational-stage program. 5 Core Points: * Unprecedented Response in Pancreatic Cancer: In heavily pretreated (3L) MTAP-deleted PDAC—where historical chemotherapy response rates hover under 15%—the combination with daraxonrasib delivered an 82% ORR and an 88% 9-month progression-free survival (PFS) rate, with zero progressive disease at data cutoff. * Flawless Safety at Registrational Dose: Zero dose-limiting toxicities (DLTs) and 0% treatment-related discontinuations were observed at the recommended Phase 3 dose; treatment-related adverse events were predominantly low-grade (stomatitis, rash), with a manageable 15%–20% dose-reduction rate. * Direct Leap to Frontline (1L): Tango is bypassing incremental niche trials to advance directly into a randomized, global Phase 3 trial against standard-of-care chemotherapy in first-line pancreatic cancer, capturing a substantially larger multi-billion-dollar addressable market. * $1B Balance Sheet Shield: With roughly $1.0 billion in cash and marketable securities, the company is fully funded through pivotal Phase 3 milestones, eliminating the near-term dilution and discounted secondary offering overhang typical of clinical biotechs. * Asymmetric Risk/Reward on the Tape: Wall Street consensus price targets remain anchored around $43–$45 (implying 80%+ upside). With elevated short interest and an overblown initial tape flush, any exhaustion in selling volume provides the setup for a rapid technical mean reversion.

$TNGX i am Pharmacist, idiot. I am coming from this industry... No rush, soon we will see who is the clown.

$TNGX Beware of this stock. It's a speculative stock, not one used for scientific or medical purposes. Number of trade orders vs volume in normal days is very strange ... I am sure 10000000% it will sink after they suck all small investors

$TNGX: Tango Therapeutics reported pancreatic Phase 1/2 data with an 82% objective response rate; plans a registrational Phase 3 trial in the first half of 2027.

$TNGX the normal pattern for this to take enough break before last sell news spike. over past months, i kept watching the order book on hourly basis. it was interesting for me to do so, i saw how cheaty they manipulate and pump that stock price. also it is obvious the paid advisors who release target recommendations in specific timings, happended twic clearly, last 30 spike and today .. lol he said $55

$TNGX We did a deep dive on Tango Therapeutics. 🏢 Tango Therapeutics is a cancer drug developer with no product sales whose lead drug, vopimetostat, targets tumors that have lost the MTAP gene 📉 Paired with Revolution Medicines' daraxonrasib, vopimetostat shrank tumors in 82% of 22 previously treated pancreatic patients, down from 92% of 12 in June, but only half had a confirmed response at the cutoff 📈 The bull read is durability: 88% had not progressed at nine months and no second-line patient has, though the 95% range runs from 60% to 97% ⚠️ The bear read starts with supply: the planned 484-patient Phase 3 needs daraxonrasib, which Tango does not own and has not secured, and 40% of patients at the chosen dose had Grade 3 side effects 📅 Tango's poster at a European cancer meeting on October 25, 2026 comes first, then the lung cancer and TNG456 data in January 2027 and a Phase 3 start in the first half of 2027 Full report linked in the replies.

$TNGX Follow-up: Tango cuts about 14% of staff, deprioritizes new-target discovery, delays two readouts to January 2027. ✂️ On October 22, 2026 the board of Tango, a Boston cancer drug developer, approved a plan to deprioritize novel target discovery and cut about 14% of the workforce, mostly in research, to focus on its PRMT5 drugs vopimetostat and TNG456 ⚠️ The vopimetostat lung cancer monotherapy data and the first TNG456 data, both guided on August 11, 2026 for the second half of 2026, are now expected in January 2027 📅 For scale, Tango held $1.01 billion of cash and investments on June 30, 2026; the 8-K gives no savings figure for the cut 📅 Next: Lung cancer and TNG456 data in January 2027; front-line Phase 3 start targeted for the first half of 2027, though Tango is still securing daraxonrasib supply for it Source: SEC 8-K, Oct 23 + SEC 8-K, Aug 11

$TNGX 🏥 Marengo Therapeutics Inc. received a second U.S. FDA Fast Track Designation for Invikafusp alfa for tissue-agnostic TMB-high solid tumors that progress after prior therapy.

$TNGX The spotlight is on tango! Look the interest of RVMD, and the curiosity of JPMorgan

Stifel⬆️ $TNGX's PT to $55, maintained Buy and said -- TNGX presented updated vopimetostat+daraxonrasib data and disclosed Ph3 1L PDAC regulatory alignment with trial initiation in 1H27. $RVMD $IMRX ERAS ANL BBOT VSTM Stifel added—TNGX also announced de-prioritization of novel target discovery (~14% workforce reduction) to focus on vopimetostat and TNG456, with Vopi NSCLC and TNG456 updates now expected in Jan-27. We raise peak sales to ~$7.1B (previously ~$4.9B), potentially still conservative. We maintain our Buy rating and raise TP to $55 (previously $40).

$TNGX 🏥 Marengo Therapeutics presented Phase 2 STARt-001 results showing invikafusp alfa achieved an 18% objective response rate, 60% disease control rate, and tumor shrinkage in 56% of evaluable patients across eight TMB-H solid tumor types in a heavily pretreated population. Prioritized by relevance

$TNGX Tango's pancreatic combo response rate slips to 82% from 92% on more patients. 📉 The response rate in 22 second- and third-line MTAP-deleted pancreatic cancer patients was 82% at the August 20, 2026 cutoff, down from 92% in the June 2026 data, and 7 of the 18 responses were unconfirmed at the cutoff, though the company says all were confirmed later, while 88% of patients were still progression-free at 9 months 🏦 Tango held $1.01 billion of cash and investments on June 30, 2026, which it expects to fund its current operating plan, against a Q2 2026 net loss of $55.3 million, and an August 11 at-the-market program allows up to $400 million in stock sales, about 8.5% more shares at the $27.93 close at 16:00 ET on October 22, 2026 📅 Next: Phase 3 start expected in the first half of 2027, plus talks with regulators on a second-line approval Source: GlobeNewswire release, Oct 23 + SEC 8-Ks, Aug 11

$TNGX 🏥 Tango Therapeutics reported Phase 1/2 data for vopimetostat plus daraxonrasib in 2L/3L pancreatic cancer with an 82% objective response rate, median PFS not reached, and 88% 9-month PFS rate, and plans a registrational Phase 3 trial in front-line MTAP-deleted pancreatic cancer in 1H 2027. Timely market event

Latest company news, October 16, 2026: Tango Therapeutics set its ESMO 2026 schedule for updated vopimetostat data with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic and lung cancer: abstract online October 19, investor webcast October 23, poster 3149P on October 25 in Madrid. $TNGX Details on our site. Not investment advice.